Clinical trials: Dual Antiplatelet Therapy
ST Segment Elevation Myocardial Infarction
Anfibatide Treatment in STEMI Patients
A Phase IIb clinical trial to investigate the safety and efficacy of antiplatelet thrombolysin injection for patients with ST Segment Elevation Myocardial Infarction (STEMI) before receiving PCI therapy, in order to provide…
- Trial name
- NCT02495012
- Testing
- Anfibatide
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Lee's Pharmaceutical Limited
Unstable Angina, NSTEMI
Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition
The purpose of this study is to evaluate the efficacy (reduction of major ischemic events at 6 and 12 months of follow-up) of a tailored clopidogrel therapy in patients with UA/NSTEMI undergoing PCI with stent implantation and…
- Trial name
- DANTE (NCT00774475)
- Testing
- comparison of different dosage of clopidogrel, doubled therapy
- Where
- Italy
- Volunteers
- 442 people
- Sponsor
- University of Florence
Left Main Coronary Artery Stenosis
Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)
The management of patients with unprotected left main coronary artery (LMCA) disease undergoing percutaneous coronary intervention (PCI) in contemporary interventional cardiology practice remains matter of intense debate.
- Trial name
- ULTIMATE-LM (NCT05650411)
- Testing
- LMCA PCI with Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India)., P2Y12 inhibitor-based SAPT after short DAPT, Conventional DAPT
- Where
- Switzerland
- Volunteers
- 828 people
- Sponsor
- IGLESIAS Juan Fernando
Bleeding, Thrombosis
Occurrence of Bleeding and Thrombosis During Antiplatelet Therapy in Non-cardiac Surgery
Research questions: 1. What is the absolute risk reduction for in-hospital major adverse cardiac events (MACE) associated with the use of dual anti-platelet therapy as compared with aspirin alone in this population? 2.
- Conditions
- Bleeding, Thrombosis, Cardiac Events
- Trial name
- OBTAIN (NCT01358422)
- Where
- 3 sites in Germany, Netherlands and 1 more
- Volunteers
- 830 people
- Sponsor
- European Society of Anaesthesiology
Stable Angina, Unstable Angina
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial
We had little experience in coronary intervention with recently introduced newer drug-eluting stent (DES) platforms, despite great anticipation, and optimal duration of dual antiplatelet therapy (DAPT) for these stent systems…
- Conditions
- Stable Angina, Unstable Angina, Non-ST Segment Elevation Myocardial Infarction
- Trial name
- HOST-IDEA (NCT02601157)
- Testing
- 3-months DAPT, 1-year DAPT
- Where
- 12 sites in South Korea
- Volunteers
- 2,173 people
- Sponsor
- Seoul National University Hospital
Coronary Artery Disease, Clopidogrel Resistance
The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models
The study purposed to learn how clopidogrel-based antiplatelet treatment for preventing adverse cardiovascular events after ePCI works in chronic coronary artery disease when guided by personal genetic characteristics for drug…
- Conditions
- Coronary Artery Disease, Clopidogrel Resistance, Coronary Thrombosis, Adverse Cardiac Events
- Trial name
- NCT06665919
- Testing
- CYP2C19 Genotype-Guided Clopidogrel Treatment, CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel, The Conventional Clopidogrel Treatment
- Where
- 4 sites in Georgia
- Volunteers
- 283 people
- Sponsor
- Vistamedi Ltd.
Myocardial Infarction, Cardiovascular Disease
Randomized, Open Label Trial of 6 Months Versus 12 Months DAPT After Drug-Eluting Stent in STEMI
OBJECTIVE OF THE STUDY: To test the hypothesis that 6 months DAPT (Dual anti-platelet therapy) after second generation DES (Drug Eluting Stent) implantation in STEMI (ST elevation Myocardial Infarction) is not inferior to 12…
- Trial name
- DAPT-STEMI (NCT01459627)
- Testing
- 6 months DAPT, 12 months DAPT
- Where
- 16 sites in Netherlands, Norway and 2 more
- Volunteers
- 1,100 people
- Sponsor
- Maasstad Hospital
Coronary Artery Disease
PITT PCI Xience Registry
Stents are devices utilized to treat cholesterol blockages of the coronary (heart) arteries. The introduction of drug-eluting (coated) stents into clinical practice is regarded as a revolutionary breaktrhough, as it has reduced…
- Trial name
- NCT01299207
- Where
- United States
- Volunteers
- 2,506 people
- Sponsor
- University of Pittsburgh
Thrombosis, Myocardial Infarction
Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients
The investigators will be comparing the effects of two different drug treatment strategies, in patients with history of a heart attack, on different markers of bleeding and clotting risk.
- Trial name
- DEFINE CCS (NCT05116995)
- Testing
- Rivaroxaban, Ticagrelor
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Nova Scotia Health Authority
Gastritis, Gastroduodenal Ulcer
Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
The purpose of this study is to evaluate effectiveness of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention.
- Trial name
- DAPTALBIS (NCT02175186)
- Testing
- ALBIS
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Young-Hak Kim, MD, PhD
Acute Coronary Syndrome
Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention and Everolimus-eluting Stents
The SORT OUT XII dual antiplatelet treatment (DAPT) duration trial, is a clinical randomized controlled superiority and non-inferiority trial to compare whether prasugrel alone versus prasugrel plus aspirin from month 1 to month…
- Trial name
- SORT OUT DAPT (NCT06718179)
- Testing
- Short duration of aspirin and prasugrel, Conventional duration of aspirin and prasugrel
- Where
- 3 sites in Denmark
- Volunteers
- 130 people
- Sponsor
- Odense University Hospital
Cardiopulmonary Arrest With Successful Resuscitation, ACS - Acute Coronary Syndrome
Add-on Cangrelor in STEMI-triggered Cardiac Arrest
In patients with ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary angioplasty (PCI) P2Y12 receptor (P2Y12r) inhibition should be achieved as soon as possible.
- Conditions
- Cardiopulmonary Arrest With Successful Resuscitation, ACS - Acute Coronary Syndrome, Hypothermia, Induced
- Trial name
- NCT03273075
- Testing
- Cangrelor, Prasugrel, Ticagrelor
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Medical University of Vienna
Coronary Artery Disease, Coronary Artery Bypass Grafting
Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting
Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting trial (TOP-CABG trial) is a multicenter, randomized, double-blind, non-inferiority, parallel controlled trial.
- Conditions
- Coronary Artery Disease, Coronary Artery Bypass Grafting, Dual Antiplatelet Therapy, Bleeding
- Trial name
- TOP-CABG (NCT05380063)
- Testing
- De-escalated Dual Antiplatelet Therapy, Dual Antiplatelet Therapy
- Where
- China
- Volunteers
- 2,300 people
- Sponsor
- China National Center for Cardiovascular Diseases
Myocardial Ischemia, Hemorrhage
Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings
A single-center, randomized trial of admitted patients with ischemic heart disease receiving percutaneous coronary intervention and stent implantation will be conducted at University Hospital of Ferrara.
- Conditions
- Myocardial Ischemia, Hemorrhage, Quality of Life, Platelet Aggregation Inhibitors
- Trial name
- BATMAN (NCT02554006)
- Testing
- good clinical practice, bundle group
- Where
- Italy
- Volunteers
- 448 people
- Sponsor
- University Hospital of Ferrara
Sickle Cell Disease
A Safety Study of Eptifibatide in Patients With Sickle Cell Disease
This study will evaluate the safety of eptifibatide in sickle cell patients and how well it works during the course of painful crises.
- Trial name
- NCT00834899
- Testing
- Eptifibatide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of North Carolina, Chapel Hill
Brain Disease, Vertebral Artery Stenosis
A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge
To compare the incidence of the composite endpoints of non-fatal ischaemic stroke, transient ischaemia (TIA) and all-cause mortality at 12-month follow-up after implantation of Bridge for the treatment of symptomatic vertebral…
- Trial name
- NCT06301776
- Testing
- Ticagrelor
- Where
- China
- Volunteers
- 560 people
- Sponsor
- The Fourth Affiliated Hospital of China Medical University
High Bleeding Risk, Coronary Artery Disease
Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen
The study compares two lengths of medication therapy (a shortened versus a prolonged dual antiplatelet therapy) in order to prevent thrombus (blood cloth) formation after the successfully treatment for coronary heart disease with…
- Conditions
- High Bleeding Risk, Coronary Artery Disease, PCI
- Trial name
- MASTER DAPT (NCT03023020)
- Testing
- Aspirin, P2Y12 inhibitor
- Where
- 138 sites in Argentina, Australia and 28 more
- Volunteers
- 4,579 people
- Sponsor
- ECRI bv
Cardiovascular Diseases
The 3 Years vs 1 Year DAPT After XINSORB BRS Implantation
The aim of the SPARTA trial is to clarify the impact of extending DAPT beyond 1 year after XINSORB BRS implantation by investigating the balance of risk and benefit in a broad population of treated patients.
- Trial name
- SPARTA (NCT04501900)
- Testing
- Clopidogrel
- Volunteers
- 2,106 people
- Sponsor
- Shanghai Zhongshan Hospital
Stable Angina, Silent Myocardial Ischemia
Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.
The main objective of the SENIOR study is to establish the efficacy and safety of the everolimus eluting stent with a biodegradable abluminal polymer (SYNERGY II) associated with a short dual antiplatelet therapy (DAPT) in…
- Conditions
- Stable Angina, Silent Myocardial Ischemia, Acute Coronary Syndrome
- Trial name
- SENIOR (NCT02099617)
- Testing
- Percutaneous Coronary Intervention (PCI) with short DAPT duration with Synergy II stent, Percutaneous Coronary Intervention (PCI) with short DAPT duration with Omega stent, Percutaneous Coronary Intervention (PCI) with short DAPT duration with Rebel stent
- Where
- 44 sites in Belgium, Finland and 7 more
- Volunteers
- 1,200 people
- Sponsor
- Ceric Sàrl
Peripheral Arterial Disease, Endovascular Procedures
Short vs Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization
The primary objective of the trial is to evaluate short versus long duration dual antiplatelet therapy in patients undergoing lower extremity endovascular revascularization.
- Trial name
- NCT02433587
- Testing
- Aspirin, Clopidogrel
- Where
- United States
- Sponsor
- University Hospitals Cleveland Medical Center